Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter phase II trial to assess clinical benefit of zoledronic acid with neo adjuvant endocrine treatment and the relationship between zoledronic acid use and gammadelta T cells for postmenopausal breast cancer.

Next Previous
X
Search
Trial Profile

Multicenter phase II trial to assess clinical benefit of zoledronic acid with neo adjuvant endocrine treatment and the relationship between zoledronic acid use and gammadelta T cells for postmenopausal breast cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoledronic acid (Primary) ; Letrozole
  • Indications Ductal carcinoma; Early breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 27 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 09 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan
    • 01 Aug 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top